Drug treatment ( DrugBank: - )

3 diseases

ID	Disease name (Link within this page)	Number of trials
51	Scleroderma	2
74	Prolactin secreting pituitary adenoma	1
271	Ankylosing spondylitis	2

51. Scleroderma

Clinical trials : 525 / Drugs : 565 - (DrugBank : 148) / Drug target genes : 114 - Drug target pathways : 217

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2014-001882-28-DE (EUCTR)	13/10/2014	07/08/2014	Drug treatment of patients with systemic sclerosis to prevent deterioration of pulmonary hypertension	Early Treatment of Borderline Pulmonary Arterial Hypertension Associated with Systemic Sclerosis (SSc-APAH) - EDITA	Systemic sclerosis-patients (SSc) with borderline pulmonary arterial hypertension;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]	Trade Name: Volibris Product Name: Ambrisentan	Thoraxklinik-Heidelberg gGmbH	NULL	Not Recruiting			Female: yes Male: yes	38	Phase 2	Germany
2	NCT01586663 (ClinicalTrials.gov)	January 2010	25/4/2012	Serial Night Time Position Splint on Systemic Sclerosis	Evaluation of Serial Night Time Position Splint on Range of Motion for Patients With Systemic Sclerosis	Diffuse Systemic Sclerosis	Device: Serial night time position splint;Drug: Drug treatment	Federal University of São Paulo	NULL	Recruiting	18 Years	N/A	Both	76	Phase 3	Brazil

Clinical trials : 19 / Drugs : 28 - (DrugBank : 10) / Drug target genes : 14 - Drug target pathways : 65

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03717454 (ClinicalTrials.gov)	December 1, 2018	14/10/2018	Dopamine D2 Receptors(D2R) Imaging in Prolactinomas	The Predictive Value of Positron Emission Tomography-Magnetic Resonance (PET-MR) Mediated Dopamine D2 Receptors Imaging in the Drug Therapy of of Prolactinomas.	Prolactinoma	Other: Surgery;Drug: Drug treatment	Zhebao Wu	Xinqiao Hospital of Chongqing;First Hospital of China Medical University;Beijing Tiantan Hospital;First Affiliated Hospital of Wenzhou Medical University;First Affiliated Hospital of Fujian Medical University;Peking Union Medical College Hospital;Huashan Hospital;Chinese PLA General Hospital	Not yet recruiting	18 Years	65 Years	All	50	N/A	NULL

Clinical trials : 574 / Drugs : 359 - (DrugBank : 68) / Drug target genes : 41 - Drug target pathways : 146

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02469753 (ClinicalTrials.gov)	October 23, 2015	9/6/2015	Interest of Continuous Non-Steroidal Anti-Inflammatory Drug Treatment in Ankylosing Spondylitis Patients Treated by Anti-TNF Therapy in the Prevention of Radiographic Outcomes	Interest of Continuous Non-Steroidal Anti-Inflammatory Drug Treatment in Ankylosing Spondylitis Patients Treated by Anti-TNF Therapy in the Prevention of Radiographic Outcomes	Ankylosing Spondylitis	Drug: NSAIDs;Drug: anti-TNF	University Hospital, Bordeaux	NULL	Active, not recruiting	18 Years	N/A	All	188	Phase 3	France;Monaco
2	NCT01038011 (ClinicalTrials.gov)	June 2004	15/12/2009	Efficacy and Safety of Risedronate (Actonel), a Third Generation Bisphosphonate in Patients With Ankylosing Spondylitis: a Phase 2 Pilot Study		Ankylosing Spondylitis	Drug: drug treatment	University of Zurich	Sanofi	Completed	18 Years	N/A	All		Phase 2	Switzerland